The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Related News Articles

Headline
In this conversation, Dave Newman, M.D., vice president and chief medical officer for virtual care at Sanford Health, discusses how innovative virtual care…
Headline
The AHA participated Feb. 18 at ViVE, a health care conference in Nashville focusing on digital health technology. Chris DeRienzo, M.D., AHA senior vice…
Headline
Today the Drug Enforcement Administration and Department of Health and Human Services announced that the effective date for the final rule regarding…
Headline
The Trump administration yesterday announced it issued executive orders authorizing 25% tariffs on all steel and aluminum imports. Importantly, both steel and…
Headline
In the latest issue of AHA's Trustee Insights newsletter, James Liggins, Jr., 2025 AHA Committee on Governance chair and board chair of Bronson Healthcare…
Headline
The AHA Center for Health Innovation released a new report to guide hospital and health system executives on using artificial intelligence and AI-powered…